The SIBERIA trial evaluated one hundred patients who qualified for carotid revascularization with high risk for surgery and were randomized 1:1 to either CGuard or Acculink™. Primary endpoints were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results